Conformational Transitions in Factor VIIa: Can We Stabilize the Inactive Form of the Enzyme?

• References

• 1 Lesk AM, Fordham WD. Conservation and variability in the structures of serine proteases of the chymotrypsin family. J Mol Biol 1996; 258: 501-37.
• 2 Perona JJ, Craik CS. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem 1997; 272: 29987-90.
• 3 Stubbs MT, Oschkinat H, Mayr I, Huber R, Angliker H, Stone SR, Bode W. The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur J Biochem 1992; 206: 187-95.
• 4 Bode W, Turk D, Karshikov A. The refined 1.9-Å X-ray crystal structure of D-Ph-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active site geometry, and structure-function relationships. Protein Sci 1992; 01: 426-71.
• 5 Mathews II, Padmanabhan KP, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck CW, Coughlin SR, Fenton 2nd JW. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry 1994; 33: 3266-79.
• 6 De Cristofaro R, De Candia E, Picozzi M, Landolfi R. Conformational transitions linked to active site ligation in human thrombin: effect on the interaction with fibrinogen and the cleavable platelet receptor. J Mol Biol 1995; 245: 447-58.
• 7 Pike AC, Brzozowski AM, Roberts SM, Olsen OH, Persson E. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Proc Natl Acad Sci USA 1999; 96: 8925-30.
• 8 Le Bonniec BF, Betz A, Guinto ER, Esmon CT, Stone SR. Mapping of the thrombin des-ETW conformation by using site-directed mutants of hirudin. Evidence for the induction of nonlocal modifications by mutagenesis. Biochemistry 1994; 33: 3959-66.
• 9 van de Locht A, Bode W, Huber R, Le Bonniec BF, Stone SR, Esmon CT, Stubbs MT. The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin. EMBO J 1997; 16: 2977-84.
• 10 Eigenbrot C, Kirchhofer D, Dennis MS, Santell L, Lazarus RA, Stamos J, Ultsch MH. The factor VII zymogen structure reveals reregistration of beta strands during activation. Structure 2001; 09: 627-36.
• 11 Perutz MF. Mechanisms of cooperativity and allosteric regulation in proteins. Q Rev Biophys 1989; 22: 139-237.
• 12 Jin J, Perera L, Stafford D, Pedersen L. Four loops of the catalytic domain of factor via mediate the effect of the first EGF-like domain substitution on factor via catalytic activity. J Mol Biol 2001; 307: 1503-17.
• 13 Dennis MS, Eigenbrot C, Skelton NJ, Ultsch MH, Santell L, Dwyer MA, O’Connell MP, Lazarus RA. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 2000; 404: 465-70.
• 14 Dennis MS, Roberge M, Quan C, Lazarus RA. Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa. Biochemistry 2001; 40: 9513-21.
• 15 Roberge M, Santell L, Dennis MS, Eigenbrot C, Dwyer MA, Lazarus RA. A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors. Biochemistry 2001; 40: 9522-31.
• 16 Örning L, Fischer PM, Hu CK, Agner E, Engebretsen M, Husbyn M, Petersen LB, Orvim U, Llinas M, Sakariassen KS. A cyclic pentapetide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation. Thromb Haemost 2001; 87: 13-21.
• 17 Kemball-Cook G, Johnson DJ, Takamiya O, Banner DW, McVey JH, Tuddenham EG. Coagulation factor VII Gln100 → Arg. Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function. J Biol Chem 1998; 273: 8516-21.
• 18 Kavlie A, Örning L, Grindflek A, Stormorken H, Prydz H. Characterization of a factor VII molecule carrying a mutation in the second epidermal growth factor-like domain. Thromb Haemost 1998; 79: 1136-43.
• 19 Peyvandi F, Jenkins PV, Mannucci PM, Billio A, Zeinali S, Perkins SJ, Perry DJ. Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. Thromb Haemost 2000; 84: 250-7.
• 20 Brundish D, Bull A, Donovan V, Fullerton JD, Garman SM, Hayler JF, Janus D, Kane PD, McDonnell M, Smith GP, Wakeford R, Walker CV, Howarth G, Hoyle W, Allen MC, Ambler J, Butler K, Talbot MD. Design and synthesis of thrombin inhibitors: analogues of MD-805 with reduced stereogenicity and improved potency. J Med Chem 1999; 42: 4584-603.
• 21 Skordalakes E, Dodson GG, Green DS, Goodwin CA, Scully MF, Hudson HR, Kakkar VV, Deadman JJ. Inhibition of human alpha-thrombin by a phosphonate tripeptide proceeds via a metastable pentacoordinated phosphorus intermediate. J Mol Biol 2001; 311: 549-55.
• 22 Bostwick JS, Bentley R, Morgan S, Brown K, Chu V, Ewing WR, Spada AP, Pauls H, Perrone MH, Dunwiddie CT, Leadley Jr RJ. RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit. Thromb Haemost 1999; 81: 157-60.
• 23 Wong PC, Crain EJ, Knabb RM, Meade RP, Quan ML, Watson CA, Wexler RR, Wright MR, Slee AM. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther 2000; 295: 212-8.
• 24 Maignan S, Guilloteau JP, Pouzieux S, Choi-Sledeski YM, Becker MR, Klein SI, Ewing WR, Pauls HW, Spada AP, Mikol V. Crystal structures of human factor Xa complexed with potent inhibitors. J Med Chem 2000; 43: 3226-32.
• 25 Callas D, Fareed J. Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thromb Haemost 1995; 74: 473-81.